Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4253-4260

  Javid, Jamsheed ^a   Mir, Rashid ^a   Julka, P K ^b   Ray, P C ^a   Saxena, Alpana ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Biomarker; Chemotherapy; Non small cell lung cancer patients; Serum cytochrome c

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOCHROME C; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOCHROME C BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; FEMALE; HISTOPATHOLOGY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TREATMENT RESPONSE; APOPTOSIS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOCHROMES C; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84938993840     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3062-6     Document Type: Article

References (12)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
2. Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R. Cancer mortality in India: a nationally representative survey. Lancet. 2012;379(9828):1807–16.
3. Lung Cancer: Survival Rates and Prognosis. National cancer Institute. 2012. http://www.cancer.gov/cancertopics/types/lung/cancer-survival-prognosis. Accessed 10 May 2012.
4. Cain K, Bratton SB, Langlais C, Walker G, Brown DG, Sun XM, et al. Apaf-1 oligomerizes into biologically active ~700-kDa and inactive ~1.4-MDa apoptosome complexes. J Biol Chem. 2000;275:6067–70.
5. Ahlemeyer B, Klumpp S, Krieglstein J. Release of cytochrome c into the extracellular space contributes to neuronal apoptosis induced by staurosporine. Brain Res. 2002;934(2):107–16.
6. Renz A, Berdel WE, Kreuter M, Belka C, Schulze-Osthoff K, Los M. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood. 2001;98(5):1542–8.
7. Barczyk K, Kreuter M, Pryjma J, Booy EP, Maddika S, Ghavami S, et al. Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer. 2005;116(2):167–73.
8. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. CHEST. 2009;136:260–71.
9. Osaka A, Hasegawa H, Tsuruda K, Inokuchi N, Yanagihara K, Yamada Y, et al. Serum cytochrome c to indicate the extent of ongoing tumor cell death. Int J Lab Hematol. 2009;31(3):307–14.
10. Renz A, Burek C, Mier W, Mozoluk M, Schulze, Osthoff K, et al. Cytochrome c is rapidly extruded from apoptotic cells and detectable in serum of anticancer drug treated tumor patients. Adv Exp Med Biol. 2001;495:331–4.
11. Nilay K, Alka J, Jeremy W, Beamer BA, Fedarko NS. Serum markers of apoptosis decrease with age and cancer stage. AGING. 2009;1(7):652–63.
12. Akemi O, Hiroo H, Yasuaki Y, Katsunori Y, Tomayoshi H, Mariko M, et al. A novel role of serum cytochrome c as a tumor marker in patients with operable cancer. J Cancer Res Clin Oncol. 2009;135:371–7.